Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atlas, Rise! Japan Cancer Center Builds Asia Trial Network

ASEAN Support, Studies Planned

Executive Summary

Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.

You may also be interested in...



Master Key Project Aims To Unlock Japan Rare Cancer Drug Development

Japan's National Cancer Center is progressing a collaborative project with industry to encourage the development of targeted therapies for rare cancers, as part of wider efforts to support early access to personalized oncology drugs.

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel